放射性粒子125^I联合高强度聚焦超声治疗肝癌的临床疗效  

Clinical feasibility of 125^I combined with high intensity focused ultrasound（HIFU） therapy for hepatocellular carcinoma

作　　者：淦宇[1,2] 李宁[1,2] 潘明志[1,2] 

机构地区：[1]四川大学华西医院胆道外科 [2]四川大学华西医院核医学科,成都610041

出　　处：《国际外科学杂志》2008年第12期800-803,共4页International Journal of Surgery

摘　　要：目的探讨应用放射性粒子125^I联合高强度聚焦超声治疗肝癌的临床疗效及可行性。方法四川大学华西医院自2006年6月-2007年4月采用放射性粒子125^I联合高强度聚焦超声治疗肝癌10例，其中5例为原发性肝癌患者，5例为肝癌术后复发患者。在治疗计划指导下，利用放射性粒子125^I联合高强度聚焦超声进行治疗。结果10例患者手术均顺利完成。所有患者术后未发生出血、感染等严重并发症，部分患者肝功能出现损害，经常规保肝治疗后恢复。术后经腹部摄片证实放射性粒子的位置无变化，于术后1、3、6月作CT复查肿瘤体积变化，提示肿瘤不同程度缩小。术后1月存活8例，术后3月存活7例，术后6月存活5例，术后1年存活2例。随访3—18个月，其中最短存活1个月，最长存活22个月，有2例患者现仍然存活。其余患者死于术后全身广泛转移。结论放射性125^I粒子和高强度聚焦超声联合应用具有安全、微创及并发症发生率低的特点，是综合治疗肝癌的有效手段之一。Objective To evaluate the efficacy and clinical feasibility of 125^I combined with high intensity focused ultrasound（HIFU） therapy for hepatocellular carcinoma. Methods The study included 10 cases of hepatocellular carcinoma（ primary hepatic carcinoma, 5 cases. Tumor recurrence of hepatocellular earcinoma after hepatecomy,5 cases）. All the cases were treated with 125^I combined with HIFU. Results The operation was successfully completed in all the cases. No severe post-operative complication occurred. CT scan found no displacement of 125^I seeds. CT scan showed that reduced size of tumor changed in different degree. The 1 month, 3 month,6 month and 1 year survival cases were 8,7,5 and 2. During 3 to 18 months follow up,2 cases died within 1 month. Two cases survived more than 22 months. Conclusion Using 125^I combined with HIFU is safe, minimally invasive and effective for treatment of hepatocellular carcinom.

关 键 词：高强度聚焦超声 125^I粒子 肝癌 

分 类 号：R735.7[医药卫生—肿瘤]